title: [Management of type 2 diabetes in 2010. Insulins and injectable drugs: role of the general practitioner].
abstract: Type 2 diabetes mellitus is a complex metabolic disease inducing an important rise of the cardiometabolic risk. Medical care must therefore be targeted to multiple risk factor reduction and address all modifiable risk factors (high LDL-cholesterol, low HDL, hypertension, hyperglycaemia, tobacco), as well as sedentarity and obesity. Glycaemic control aimed to achieve HbA1C < 7% is associated with a reduction in microvascular and macrovascular complications. Unfortunately, many patients do not reach these therapeutic targets. This progressive disease correlates with an inexorable destruction of the beta cells, therefore the therapeutic options must regularly be upgraded. The use of injectable drugs (GLP-1 agonists and insulins) are part of the general practitioner's therapeutic arsenal.
authors.affiliation: Service de Médecine Interne, C.H. Tubize-Nivelles, Entité Jolimontoise. benoit.renneboog@skynet.be
authors.forename: B
authors.initials: B
authors.lastname: Renneboog
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D003663:Decision Trees; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D058006:General Practice; D006801:Humans; D007267:Injections; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007328:Insulin